Financing through stock acquisition rights with adjustment clauses for the exercise price
First written in FY2021-Q1. 2 of 4 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2021.
24 other companies' latest entry also says "Achieved".
- FY2021AchievedAnnual report
「All of the stock acquisition rights had been exercised as of 2 September 2020, raising ¥5,156,837,000.」
Exercise of all 3,500 of the fifth series of stock acquisition rights with provisions for adjustment of the exercise price was completed, resulting in the issue of 700,000 shares and funding of ¥5,156,837,000. - FY2021-Q3AdvancedAnnual report
「During the third quarter, share acquisition rights relating to bonds with share acquisition rights and other instruments with an exercise price adjustment clause were exercised as follows.」
During the third quarter, 319 stock acquisition rights were exercised, 63,800 shares were issued, and ¥425,455,000 was raised. Cumulatively through the end of the third quarter, the figures were 3,500 rights, 700,000 shares and ¥5,156,837,000, respectively. - FY2021-Q2AdvancedAnnual report
「During the second quarter, the stock acquisition rights related to stock acquisition rights, etc. with adjustment provisions for the exercise price were exercised as follows.」
During the second quarter, 6,362 of the fifth series of stock acquisition rights were exercised, 636,200 shares were issued, and ¥4,725,033,000 was raised. The exercise of the stock acquisition rights also increased share capital and the capital surplus by ¥2,371,101,000 each. - FY2021-Q1First statedAnnual report
「At a meeting of the board of directors held on 8 June 2020, the company resolved to issue, by way of a third-party allotment, the fifth series of stock acquisition rights with provisions for adjustment of the exercise price, as follows: 3,500 stock acquisition rights; 350,000 potential shares; funding amount (estimated net proceeds), ¥7,371,650,000; exercise period, 26 June 2020 to 27 June 2022.」
The company began financing through a third-party allotment of the fifth series of stock acquisition rights, with estimated net proceeds of ¥7,371,650,000 and 350,000 potential shares. The exercise price was subject to adjustment provisions and a floor, and the exercise period ran from 26 June 2020 to 27 June 2022.